PT - JOURNAL ARTICLE AU - Miguel Froes AU - Bernardo Neves AU - Bruno Martins AU - Mário J. Silva TI - C<span class="sc">omparison of</span> M<span class="sc">ultimorbidity in</span> COVID-19 <span class="sc">infected and general population in</span> P<span class="sc">ortugal</span> AID - 10.1101/2020.07.02.20144378 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.02.20144378 4099 - http://medrxiv.org/content/early/2020/09/08/2020.07.02.20144378.short 4100 - http://medrxiv.org/content/early/2020/09/08/2020.07.02.20144378.full AB - Understanding COVID-19 and its risk factors in the Portuguese population is critical to the struggle against this infectious disease. To study the impact of multimorbidity in the population with COVID-19 infection, we performed a descriptive analysis of a dataset extracted from all reported confirmed cases of COVID-19 in Portugal until June 30, 2020. We observed a prevalence of multimorbidity in 6.77% of the 36,244 infected patients. These patients showed an increased risk of hospitalization, ICU admission, and mortality with OR 2.22 (CI 95%: 2.13-2.32) for every additional morbidity. Further studies should confirm these findings and special attention should be made on data collection, to ensure proper recording of patient comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee: "Comissao de Etica do IST", " http://etica.tecnico.ulisboa.pt/" Study previously authorized by the IST-EC according to waht was made public in: " https://drive.tecnico.ulisboa.pt/download/288548787958179" Ref. n 9/2020 (CE-IST) Date: 20/04/2020 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis retrospective observational study used data provided by DGS after the required institutional and ethical approvals. The sample population consists of all the Portuguese population with SARS-CoV2 confirmed infection as notified by clinicians by June 30, 2020. A broad range of clinical and demographic variables are present in this dataset. In this study we specifically used age, gender, hospital admission, admission in intensive care unit, mortality and patient's underlying conditions.